• Identifies medications with significant gene-drug interactions (GDIs) to inform prescribing
  • Drives change in clinical decision-making; demonstrates a 74% relative decrease in use of drugs with GDIs1
  • Level 1 evidence demonstrates 49% relative improvement in remission2

    Fact Sheets and Product Info:

    Executive Summary Download PDF
    Clinical Dossier Download PDF
    Digital Dossier View Dossier
    Combinatorial Pharmacogenomics White Paper Download PDF


    About Mental Health: Major Depressive Disorder

    1 in 6 Americans develop major depressive disorder in their lifetime. Medications serve as the primary course of care for this condition, yet fewer than half of all depressed patients respond well to their first prescription and overall treatment failure rates exceed 50%.

    This high failure rate is compounded by the fact that six weeks are typically necessary to observe the effectiveness of MDD medications, a timeline aggravated by the common approach of starting patients on low doses and making gradual increases in order to avoid significant side effects. Patients also become less responsive and less adherent with each subsequent medication, and the likelihood of an adverse event increases.

    About GeneSight:

    GeneSight Psychotropic is a pharmacogenomic test that analyzes genes involved in pharmacokinetics and pharmacodynamics to weigh their combined influence on patient response to psychotropic medications. This combinatorial approach used only by GeneSight has been demonstrated to drive improved patient outcomes in multiple clinical studies. GeneSight guides prescribing clinicians by placing each medication into one of three color-coded categories: “Use as Directed” in green, “Moderate Gene-Drug Interaction” in yellow, or “Significant Gene-Drug Interaction” in red. This categorization enables physicians to select genetically appropriate medications for each patient, increasing the likelihood of response and reducing the risk of adverse events.


    1. Thase ME, et al. J Clin Psychiatry 2019;80(6).
    2. Brown LC, et al. Pharmacogenomics. 2020 Jun;21(8):559-569.
    3. Note: Not all patients who receive the GeneSight Psychotropic test will experience improvements in symptoms, achieve response, or achieve remission.

    Myriad Products